Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek® in adult patients with overactive bladder
"Purpose: Mirabegron, the first-in-class beta-3 agonist, is the mainstay medication for overactive bladder (OAB). The aim of this study was to investigate the efficacy and safety of generic drugs of mirabegron (Mirabek®) in adults diagnosed with OAB through a multicenter, prospective, non-inter...
Saved in:
Main Authors: | Jee Soo Park, Won Sik Jang, Jongchan Kim, Moon-Hwa Park, Won Sik Ham |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Urological Association
2025-01-01
|
Series: | Investigative and Clinical Urology |
Subjects: | |
Online Access: | https://www.icurology.org/pdf/10.4111/icu.20240278 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Does Mirabegron the β3 Agonist Frequently Used in the Treatment of Overactive Bladder Really Affect the Respiratory System Negatively ? A Prospective Study
by: Şenol Adanur, et al.
Published: (2024-12-01) -
Comparison Of Outcome And Side Effects Profile Of Treatment Of Overactive Bladder With Different Classes Of Drugs
by: Nazish Sarfraz, et al.
Published: (2023-12-01) -
An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder
by: Zhipeng Zhang, et al.
Published: (2025-01-01) -
Mirabegron, a breakthrough in overactive bladder syndrome?
by: Almudena Maestro Nombela, et al.
Published: (2017-05-01) -
The Management of Children and Adolescents with Overactive Bladder Refractory to Treatment with Parasacral Transcutaneous Electrical Nerve Stimulation
by: Carlos Eduardo Rocha Macedo, et al.
Published: (2025-01-01)